Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pfizer’s exec team is hit with a double whammy as another c-suite leader announces his retirement.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here’s a look.
With the planned departure from its 561,652-square-foot RTP campus, GSK will reduce its geographical footprint, but not its staff.
The idea is not just a flight of fancy by a brilliant mind with big dreams. It is part of a larger de-extinction strategy aimed at solving climate change.
After serving three presidential administrations, Dr. Francis S. Collins is stepping down as director of the National Institutes of Health at the end of the year.
The DOL’s Office of Federal Contract Compliance Programs found that AstraZeneca paid a much lower base salary than similar employees to 23 Hispanic female staff and 295 female employees.
The deal has a value of over one billion dollars, with highlights for Xencor including receiving a $100 million upfront payment, a $25 million equity investment, eligibility for plamotamab royalties and potential milestone payments worth up to $1.18 billion.
Once the deal is done, the company will be renamed MoonLake Immunotherapeutics and trade on the Nasdaq under the ticker symbol MLTX.
This week, three global biopharmaceutical companies received over half a billion dollars to support research and development initiatives in the treatment of rare and deadly diseases.